Author/Authors :
Ebrahimi, Parvin Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Farhadi, Zeynab Department of Health Services Management - School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Behzadifar, Masoud Health Management and Economics Research Center - Iran University of Medical Sciences, Tehran, Iran , Shabaninejad, Hosein Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Abolghasem Gorji, Hassan Department of Health Services Management - School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Taheri Mirghaed, Masood Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Salemi (MSc), Morteza Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Amin, Kamyar Department of Cardiology - , Babol University of Medical Sciences, Babol, Iran , Mohammadibakhsh, Roghayeh Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran , Luigi Bragazzi, Nicloa Department of Health Sciences (DISSAL) - University of Genoa, Genoa, Italy , Sohrabi, Rahim Department of Health Services Management, School of Health Management and Information Sciences - Iran University of Medical Sciences, Tehran, Iran
Abstract :
Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue. Aspirin continues to be the major gold-standard treatment worldwide in the prevention of thrombotic disease in patients with CVD, even though not all individuals respond to antiplatelet therapy in a similar way, being resistant to aspirin. The aim of this study was to determine the prevalence of laboratory defined aspirin resistance in CVD patients worldwide.
Methods: Relevant articles were identified through searching EMBASE, PubMed/ MEDLINE, ISI /Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa scale. The pooled prevalence of laboratory defined aspirin resistance was computed using the Der Simonian-Laird random-effect model.
Results: We included 65 studies, with a total of 10,729 patients. The overall prevalence of laboratory defined aspirin resistance in CVD patients was 24.7% ([95%CI 21.4-28.4]. Women were found to be at increased risk of laboratory defined aspirin resistance compared to men, with an odds ratio of 1.16 [95%CI 0.87-1.54].
Conclusion: Doctors and healthcare providers should pay special attention to aspirin resistance since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses.
Keywords :
Prevalence , Aspirin resistance , meta-analysis , systematic review , cardiovascular disease , Aspirin resistance
